Company / Capital Expenditures
Bicara Therapeutics Inc. Capital Expenditures History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$71.0K
FY2024
5-year range
$71.0K / $586.0K
FY2023-FY2024
Trend
-87.9%
vs FY2023
Sector context
#172 of 194
Health Care
What the data says
Bicara Therapeutics Inc.'s capital expenditures of $71,000 is lower than 89% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
$71,000 in FY2024.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 194This company $71.0K Sector average $117.5M
▼
-99.9% below sector average
Key checks
Key Insights
- In FY2024, capital expenditures decreased 87.9% year-over-year.
- Ranks #172 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 11.58 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $71.0K | -87.9% |
| FY2023 | $586.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026